Clinical Trial

Disease: Alpha 1-Antitrypsin Deficiency, AATD, (NCT06389877)

Disease info:

Alpha-1 antitrypsin deficiency (AATD) is an inherited genetic disorder that is most commonly caused by a G-to-A point mutation in the SERPINA1 gene. This mutation results in the production of insufficient levels of circulating M-AAT protein, which protects the lungs from proteolytic enzymes, and aggregation of misfolded Z-AAT protein in hepatocytes. This leads to lung and liver disease. Individuals with AATD have Z mutations on both alleles, known as the PiZZ genotype.

Augmentation therapy via delivery of functional AAT protein is currently the only treatment option for AATD lung disease and requires weekly intravenous infusions. There are no treatments for AATD liver disease, other than liver transplantation.


There are approximately 200,000 patients in the United States and Europe who have Z mutations on both alleles.
Official title:
A Phase 1/2 Dose-exploration and Dose-expansion Study to Evaluate the Safety and Efficacy of BEAM-302 in Adult Patients With Alpha-1 Antitrypsin Deficiency (AATD)-Associated Lung Disease and/or Liver Disease


Phone: 857-327-8641



United Kingdom, London
Clinical Study Center, London, United Kingdom

Study start:
May. 1, 2024
106 participants
Gene editing method:
Base editing
Type of edit:
Gene correction
PiZ variant of the SERPINA1 gene
Delivery method:
Lipid-nanoparticle (LNP) - In-vivo
IND Enabling Pre-clinical
Phase I Safety
Phase II Safety and Dosing
Phase III Safety and Efficacy

Status: Not yet recruiting


This is a Phase 1/2, multicenter, open-label, dose-exploration (Phase 1) and dose-expansion (Phase 2) study to evaluate the safety, tolerability, PK/PD, and efficacy of BEAM-302 in adult patients with AATD-associated lung disease and/or liver disease and to determine the optimal biological dose (OBD).

Last updated: May. 13, 2024
Search CRISPR Medicine